Opinion · United States Court of Appeals for the Federal Circuit
IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010)
In re OMEPRAZOLE Pat. LITIGATION. Astrazeneca AB, Aktiebolaget Hassle,KBI-E, Inc., KBI, Inc., & Astrazeneca LP, Plaintiffs-Appellees, v.Mylan Laboratories Inc. (now known as Mylan Inc.), Mylan PharmaceuticalsInc., Laboratories Dr. Esteve, S.A. & Esteve Quimica, S.A.,Defendants-Appellants., 412 F. App'x 297 (Fed. Cir. 2010)
- Type
- Opinion
- Court
- United States Court of Appeals for the Federal Circuit
- Jurisdiction
- Federal
- Date
- 2011-03-08
- Topic
- general
IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010) In re OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle,KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellees, v.Mylan Laboratories Inc. (now known as Mylan Inc.), Mylan PharmaceuticalsInc., Laboratories Dr. Esteve, S.A. and Esteve Quimica, S.A.,Defendants-Appellants.
Citator
UpLaw has not yet analyzed IN RE OMEPRAZOLE PATENT LITIGATION, 412 Fed.Appx. 297 (Fed. Cir. 2010). The absence of a flag is not a finding that it is good law.
James H. Wallace, Jr., Wiley Rein, LLP, of Washington, DC, argued for defendants-appellants. With him on the brief were Mark A. Pacella and Brian H. Pandya.
ORDERED and ADJUDGED:AFFIRMED.SeeFed. Cir. R. 36.
- [EDITOR'S NOTE: This case is unpublished as indicated by the issuing court.] ↩